Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review

British Medical Journal

Volumn 335, Issue 7618, 2007, Pages 497-501

  Eurich, Dean T ^a   McAlister, Finlay A ^b   Blackburn, David F ^c   Majumdar, Sumit R ^b   Tsuyuki, Ross T ^b   Varney, Janice ^a   Johnson, Jeffrey A ^d  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLYCOSIDASE INHIBITOR; INSULIN; INSULIN DERIVATIVE; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DATA BASE; DIABETES MELLITUS; DIET; HAZARD RATIO; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RISK; SYSTEMATIC REVIEW;

DIABETIC ANGIOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 34548603259     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39314.620174.80     Document Type: Article

References (8)

1. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007;99(4A):113B-32B.
2. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91.
3. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.; Epidemiol Commun Health 1998;52:377-84.
4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.
6. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
7. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94.
8. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-74.